Company intelligence / Profile preview

Valens

Baltimore, Maryland, United Statesvalens.com ↗

Ownership: Private
Development stage: Commercial

Overview

Valens Therapeutics was focused on developing therapeutic products targeting neovascular diseases—primarily pathological conditions in the eye and cancer—by addressing unregulated angiogenesis. The company aimed to build a platform technology applicable across both ophthalmology and oncology. It also provided access to GMP-qualified cleanroom suites for biologic manufacturing. No clinical-stage programs or results are reported, and the company appears inactive/dead at present.

Therapeutic areas: OncologyOphthalmology
Modalities: Biologic
Industry: Biotech

Partnerships

bwtech@UMBC incubator/accelerator program partner/investor

Beyond the preview

Go deeper on Valens.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Valens.

Explore the full profile